{"DataElement":{"publicId":"7796037","version":"1","preferredName":"Gleason Score for Prostate Cancer Grading System Category","preferredDefinition":"Defined characteristics based on the Gleason grading system for prostatic carcinoma that distills grade groups of prostate cancer down to the lowest number of grades, each with a unique prognosis.","longName":"2547911v2.0:7796036v1.0","context":"MCL","contextVersion":"1","DataElementConcept":{"publicId":"2547911","version":"2","preferredName":"Gleason Score for Prostate Cancer Grading System","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation.","longName":"GLEASONSC_P_GD_PRSCA","context":"MCL","contextVersion":"1","ObjectClass":{"publicId":"2547908","version":"1","preferredName":"Gleason Score for Prostate Cancer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"C28084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-081C-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"SBREXT","dateModified":"2017-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2547909","version":"1","preferredName":"Gleason Grade for Prostate Cancer","preferredDefinition":"definition pending","longName":"C28107","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Grading System","conceptCode":"C28107","definition":"A grading system for prostatic carcinoma based on the microscopic glandular architectural patterns of the malignant epithelial cells. Nuclear atypia is not evaluated. It defines five patterns or grades which reflect decreasing differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-082A-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"ONEDATA","dateModified":"2006-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE29EE4F-9AEE-2DD1-E053-4EBD850A9DDC","latestVersionIndicator":"Yes","beginDate":"2021-10-12","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-12","modifiedBy":"MAESKEB","dateModified":"2021-12-02","changeDescription":"10/12/21 mr Versioned to correct property long name to match concept name. Removed 'Plus' from DEC long name. Transferred from DCP to MCL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7796036","version":"1","preferredName":"Gleason Score for Prostate Cancer Category","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._A grouping of items based on some commonality or by user defined characteristics.","longName":"7796036v1.0","context":"MCL","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not reported","valueDescription":"Not Reported","ValueMeaning":{"publicId":"2572231","version":"1","preferredName":"Not Reported","longName":"2572231","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-11-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDB1057F-5067-6E5C-E053-4EBD850A6972","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"ONEDATA","dateModified":"2021-10-06","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDB1057F-5071-6E5C-E053-4EBD850A6972","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"ONEDATA","dateModified":"2021-10-06","deletedIndicator":"No"},{"value":"High grade, 8 - 10","valueDescription":"High Grade","ValueMeaning":{"publicId":"3288211","version":"1","preferredName":"High Grade","longName":"3288211","preferredDefinition":"Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade","conceptCode":"C14158","definition":"Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6DC488-B15F-8FD1-E040-BB89AD432EE0","latestVersionIndicator":"Yes","beginDate":"2011-10-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDB1057F-5085-6E5C-E053-4EBD850A6972","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"ONEDATA","dateModified":"2021-10-06","deletedIndicator":"No"},{"value":"Intermediate grade, 7","valueDescription":"Intermediate Grade","ValueMeaning":{"publicId":"3335158","version":"1","preferredName":"Intermediate Grade","longName":"3335158","preferredDefinition":"A term referring to the degree of differentiation of a malignant neoplasm and indicating that it is moderately differentiated.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intermediate Grade","conceptCode":"C28083","definition":"A term referring to the degree of differentiation of a malignant neoplasm and indicating that it is moderately differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43D00DA-4E4B-7AC2-E040-BB89AD434B8C","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDB1057F-509A-6E5C-E053-4EBD850A6972","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"ONEDATA","dateModified":"2021-10-06","deletedIndicator":"No"},{"value":"Low grade, 6","valueDescription":"Low Grade","ValueMeaning":{"publicId":"3288210","version":"1","preferredName":"Low Grade","longName":"3288210","preferredDefinition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6DC488-B13C-8FD1-E040-BB89AD432EE0","latestVersionIndicator":"Yes","beginDate":"2011-10-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDB1057F-50AF-6E5C-E053-4EBD850A6972","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"ONEDATA","dateModified":"2021-10-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5936782","version":"1","preferredName":"Gleason Score for Prostate Cancer Category","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C28084:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"576E72DD-5EE7-3C5F-E053-F662850A5B33","latestVersionIndicator":"Yes","beginDate":"2017-08-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-23","modifiedBy":"ONEDATA","dateModified":"2017-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CDB1057F-5050-6E5C-E053-4EBD850A6972","latestVersionIndicator":"Yes","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"COLBERTM","dateModified":"2022-02-28","changeDescription":"2/28/22 mr Released per SME.   10/13/21 mr Changed length to 25 to match MCL PCA prostate DCT.   10/6/21 mr Created for MCL PCA prostate per DCT.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781145","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001794","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"gleason_grade_group","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"MCL-Template Name","type":"Data Collection Template","description":"prostate_v0_13aug2020.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"},{"name":"Gleason grade, striated","type":"Preferred Question Text","description":"Gleason grade, striated","url":null,"context":"MCL"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CDB2B21E-BCD7-1D3C-E053-4EBD850AE1DF","latestVersionIndicator":"Yes","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"COLBERTM","dateModified":"2022-02-25","changeDescription":"2/25/22 mr Released per SME.   10/13/21 mr Updated with v2 of the DEC to correct issue with long name and property. Also updated definition.   10/6/21 mr Created for MCL PCA prostate per DCT.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}